Vikram Purohit
Stock Analyst at Morgan Stanley
(1.83)
# 3,321
Out of 5,129 analysts
162
Total ratings
32.81%
Success rate
-7.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $98.84 | -4.90% | 26 | Jan 6, 2026 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $6.31 | +74.33% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $23.27 | +46.11% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $79.51 | -0.64% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.60 | +126.54% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.71 | +34.77% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $221.49 | +12.87% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $186.21 | +2.04% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.42 | +66.05% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $30.06 | +3.13% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $122.77 | -86.97% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $26.59 | -62.39% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $13.94 | -56.96% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.50 | +394.12% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $82.27 | -50.16% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $7.77 | +414.80% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.00 | +550.00% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $11.98 | +217.20% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $6.93 | +188.60% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $19.51 | -48.74% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $0.97 | +2,162.44% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $22.60 | -11.50% | 2 | Aug 5, 2020 |
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $98.84
Upside: -4.90%
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $6.31
Upside: +74.33%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $23.27
Upside: +46.11%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $79.51
Upside: -0.64%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.60
Upside: +126.54%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.71
Upside: +34.77%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $221.49
Upside: +12.87%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $186.21
Upside: +2.04%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.42
Upside: +66.05%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $30.06
Upside: +3.13%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $122.77
Upside: -86.97%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $26.59
Upside: -62.39%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $13.94
Upside: -56.96%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.50
Upside: +394.12%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $82.27
Upside: -50.16%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $7.77
Upside: +414.80%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.00
Upside: +550.00%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $11.98
Upside: +217.20%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $6.93
Upside: +188.60%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $19.51
Upside: -48.74%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $0.97
Upside: +2,162.44%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $22.60
Upside: -11.50%